The kidney in hyperuricemia and gout

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 2, 2013, Pages 216-223

  Mount, David B ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Allopurinol; colchicine; febuxostat; gout; transporter; uric acid

Indexed keywords

ALLOPURINOL; CARRIER PROTEIN; COLCHICINE; FEBUXOSTAT; FENOFIBRATE; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PEGLOTICASE; PREDNISONE; PROTEIN OAT1; PROTEIN OAT3; PROTEIN SLC5A12; PROTEIN SLC5A8; PROTEIN URAT1; UNCLASSIFIED DRUG; URATE;

ASSOCIATED HYPERSENSITIVITY SYNDROME; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIARRHEA; DIETARY INTAKE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; INTESTINE EPITHELIUM CELL; KIDNEY EPITHELIUM; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EXCRETION; LOW DRUG DOSE; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; URIC ACID BLOOD LEVEL;

ANIMALS; GOUT; HOMEOSTASIS; HUMANS; HYPERURICEMIA; KIDNEY; KIDNEY DISEASES; PROGNOSIS; URIC ACID;

EID: 84873567973     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835ddad2     Document Type: Review

References (74)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63:3136-3141.
2. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population-The National Health and Nutrition Examination Survey 2007-2008. Am J Med 2012; 125:679-687.
3. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300:924-932.
4. Doria A, Krolewski AS. Diabetes: lowering serum uric acid levels to prevent kidney failure. Nat Rev Nephrol 2011; 7:495-496.
5. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57:109-115.
6. Hooper DC, Spitsin S, Kean RB, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1998; 95:675-680.
7. Spitsin S, Koprowski H. Role of uric acid in Alzheimer's disease. J Alzheimers Dis 2010; 19:1337-1338.
8. Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009; 66:1460-1468.
9. Hershfield MS, Roberts LJ 2nd, Ganson NJ, et al. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci USA 2010; 107:14351-14356.
10. Latif W, Karaboyas A, Tong L, et al. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol 2011; 6:2470-2477.
11. Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992; 34:78-84.
12. Xu P, LaVallee PA, Lin JJ, Hoidal JR. Characterization of proteins binding to E-box/Ku86 sites and function of Ku86 in transcriptional regulation of the human xanthine oxidoreductase gene. J Biol Chem 2004; 279:16057-16063.
13. Roch-Ramel F, Guisan B. Renal transport of urate in humans. News Physiol Sci 1999; 14:80-84.
14. Guggino SE, Aronson PS. Paradoxical effects of pyrazinoate and nicotinate on urate transport in dog renal microvillus membranes. J Clin Invest 1985; 76:543-547.
15. Perez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002; 47:610-613.
16. Wright AF, Rudan I, Hastie ND, Campbell H. A 'complexity' of urate transporters. Kidney Int 2010; 78:446-452.
17. Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28 141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009; 5:e1000504.
18. Reginato AM, Mount DB, Yang I, Choi HK. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol 2012; 8:610-621.
19. Dinour D, Gray NK, Campbell S, et al. Homozygous SLC2A9 mutations cause severe renal hypouricemia. J Am Soc Nephrol 2010; 21:64-72.
20. Mount DB, Kwon CY, Zandi-Nejad K. Renal urate transport. Rheum Dis Clin North Am 2006; 32:313-331; vi.
21. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417:447-452.
22. Bahn A, Hagos Y, Reuter S, et al. Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J Biol Chem 2008; 283:16332-16341.
23. Hagos Y, Stein D, Ugele B, et al. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 2007; 18:430-439.
24. Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40:437-442.
25. Wei W, Hemani G, Hicks AA, et al. Characterisation of genome-wide association epistasis signals for serum uric acid in human population isolates. PLoS One 2011; 6:e23836.
26. Charles BA, Shriner D, Doumatey A, et al. A genome-wide association study of serum uric acid in African Americans. BMC Med Genomics 2011; 4:17.
27. Bannasch D, Safra N, Young A, et al. Mutations in the SLC2A9 gene cause hyperuricosuria and hyperuricemia in the dog. PLoS Genet 2008; 4:e1000246.
28. Urano W, Taniguchi A, Anzai N, et al. Association between GLUT9 and gout in Japanese men. Ann Rheum Dis 2010; 69:932-933.
29. Hollis-Moffatt JE, Gow PJ, Harrison AA, et al. The SLC2A9 nonsynonymous Arg265His variant and gout; evidence for a population-specific effect on severity. Arthritis Res Ther 2011; 13:R85.
30. McArdle PF, Parsa A, Chang YP, et al. Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order Amish. Arthritis Rheum 2008; 58:2874-2881.
31. Eraly SA, Vallon V, Rieg T, et al. Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics 2008; 33:180-192.
32. Van Aubel RA, Smeets PH, Van Den Heuvel JJ, Russel FG. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 2005; 288:F327-F333.
33. Woodward OM, Kottgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci USA 2009; 106:10338-10342.
34. Iharada M, Miyaji T, Fujimoto T, et al. Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem 2010; 285:26107-26113.
35. Jutabha P, Kanai Y, Hosoyamada M, et al. Identification of a novel voltagedriven organic anion transporter present at apical membrane of renal proximal tubule. J Biol Chem 2003; 278:27930-27938.
36. Jutabha P, Anzai N, Kitamura K, et al. Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem 2010; 285:35123-35132.
37. Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 2012; 3:764.
38. Wilkinson SP, Grove A. HucR, a novel uric acid-responsive member of the MarR family of transcriptional regulators from Deinococcus radiodurans. J Biol Chem 2004; 279:51442-51450.
39. Baillie JK, Bates MG, Thompson AA, et al. Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude. Chest 2007; 131:1473-1478.
40. Wu W, Dnyanmote AV, Nigam SK. Remote communication through Slc and Abc drug transporter pathways: an update on the remote sensing and signaling hypothesis. Mol Pharmacol 2011; 79:795-805.
41. Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363:1277-1281.
42. Lieber CS, Jones DP, Losowsky MS, Davidson CS. Interrelation of uric acid and ethanol metabolism in man. J Clin Invest 1962; 41:1863-1870.
43. Pascual E, Perdiguero M. Gout, diuretics and the kidney. Ann Rheum Dis 2006; 65:981-982.
44. Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA 1993; 270:354-359.
45. Egan BM, Lackland DT. Biochemical and metabolic effects of very-low-salt diets. Am J Med Sci 2000; 320:233-239.
46. Masugi F, Ogihara T, Hashizume K, et al. Changes in plasma lipids and uric acid with sodium loading and sodium depletion in patients with essential hypertension. J Hum Hypertens 1988; 1:293-298.
47. Moriwaki Y, Yamamoto T, Tsutsumi Z, et al. Effects of angiotensin II infusion on renal excretion of purine bases and oxypurinol. Metabolism 2002; 51:893-895.
48. Yamamoto T, Moriwaki Y, Takahashi S, et al. Effect of norepinephrine on the urinary excretion of purine bases and oxypurinol. Metabolism 2001; 50:1230-1233.
49. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120:442-447.
50. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-1441.
51. Hui JY, Choi JW, Mount DB, et al. The independent association between parathyroid hormone levels and hyperuricemia: a national population study. Arthritis Res Ther 2012; 14:R56.
52. Urano W, Yamanaka H, Tsutani H, et al. Kamatani N. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol 2002; 29:1950-1953.
53. Jacob RA, Spinozzi GM, Simon VA, et al. Consumption of cherries lowers plasma urate in healthy women. J Nutr 2003; 133:1826-1829.
54. Zhang Y, Neogi T, Chen C, et al. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum 2012; 64:4004-4011.
55. Haidari F Jr, Mohammad Shahi M, Keshavarz SA, Rashidi MR. Inhibitory effects of Tart Cherry (Prunus cerasus) juice on xanthine oxidoreductase activity and its hypouricemic and antioxidant effects on rats. Malays J Nutr 2009; 15:53-64.
56. Choi HK, Gao X, Curhan G. Vitamin C intake and the risk of gout in men: a prospective study. Arch Intern Med 2009; 169:502-507.
57. Cohen SD, Kimmel PL, Neff R, et al. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol 2008; 19:2204-2210.
58. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1. Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64:1431-1446.
59. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2. Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64:1447-1461.
60. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010; 62:1060-1068.
61. Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007; 57:1324-1328.
62. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306:711-720.
63. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007; 20:391-395.
64. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47-56.
65. Hung SI, Chung WH, Liou LB, et al. HLA-B-5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102:4134-4139.
66. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012; 64:2529-2536.
67. Jung JW, Song WJ, Kim YS, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2012; 26:3567-3572.
68. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001; 60:981-983.
69. Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011; 63:412-421.
70. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57:545-549.
71. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006; 33:1646-1650.
72. Uetake D, Ohno I, Ichida K, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med 2010; 49:89-94.
73. Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008; 21:1157-1162.
74. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31:2429-2432.